Rheumatoid arthritis and cardiovascular disease: An update on treatment issues

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 317-324

  Barbhaiya, Medha ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiovascular disease; coronary; rheumatoid arthritis; risk stratification; treatment

Indexed keywords

ATORVASTATIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SMOKING; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; CARDIOVASCULAR DISEASES; HUMANS; METHOTREXATE; RISK FACTORS;

EID: 84875890182     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835fd7f8     Document Type: Review

References (108)

1. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-1307.
2. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481-494.
3. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33:2167-2172.
4. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1608-1612.
5. Atzeni F, Sarzi-Puttini P, De Blasio G, et al. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann NY Acad Sci 2007; 1108:392-397.
6. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71:1524-1529.
7. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56:3583-3587.
8. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-2745.
9. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-1925.
10. Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in nonrheumatoid arthritis patients Ann Rheum Dis 2008; 67:64-69.
11. Brady SR, de Courten B, Reid CM, et al. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 2009; 36:34-40.
12. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-1925.
13. Kaushik P, Messing SP, Arora J, et al. Subcutaneous nodules are significantly associated with cardiovascular events in patients with rheumatoid arthritis: results from a very large US Registry. Arthritis Rheum 2012; 64:S361-S362.
14. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58:2268-2274.
15. Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444-3449.
16. Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multiethnic study of atherosclerosis. Semin Arthritis Rheum 2012; 41:535-544.
17. Lindhardsen J, Ahlehoff O, Gislason GH, et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2012; 71:1496-1501.
18. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk Ann Rheum Dis 2010; 69:683-688.
19. Kremers HM, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50:3450-3457.
20. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-331.
21. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50-e103.
22. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26:1701-1704.
23. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:842-845.
24. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment: a prospective, controlled study. Arthritis Res Ther 2006; 8:R82.
25. VanHalm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66:184-188.
26. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-Related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010; 69:1996-2001.
27. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70:482-487.
28. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35:107-111.
29. Popa C, Van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66:1503-1507.
30. Soubrier M, Jouanel P, Mathieu S, et al. Effects of antitumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75:22-24.
31. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38:10-20.
32. Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res 2011; 63:530-534.
33. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021.
34. Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012; 39:32-40.
35. Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology 2011; 50:324-329.
36. De Vera MA, Choi H, Abrahamowicz M, et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011; 70:1020-1024.
37. TRACE-RA-Trial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis. http://www.dgoh.nhs.uk/tracera/ default. aspxhttp://www.dgoh.nhs.uk/tracera/default.aspx [Accessed 11 December 2012].
38. Dessein PH, Joffe BI, Stanwix A, et al. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002; 29:462-466.
39. Maradit Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732.
40. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10:R30.
41. Innala L, Moller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13:R131.
42. Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2012; 78:179-183.
43. Panoulas VF, Douglas KMJ, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007; 46:1477-1482.
44. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490-496.
45. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure A meta-analysis. Ann Intern Med 1994; 121:289-300.
46. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477-484.
47. Bang SY, Lee KH, Cho SK, et al. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anticyclic citrullinated peptide antibody status. Arthritis Rheum 2010; 62:369-377.
48. Baka Z, Buzà s E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009; 11:238.
49. Albano SA, Santana-Sahagun E. Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001; 31:146-159.
50. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624-1629.
51. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Obesity in rheumatoid arthritis. Rheumatology 2011; 50:450-462.
52. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204:178-183.
53. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611-619.
54. Lemmey AB, Jones J, Maddison PJ. Rheumatoid cachexia: what is it and why is it important J Rheumatol 2011; 38:2074.
55. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599-2610.
56. Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264:295-314.
57. Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206:61-68.
58. Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011; 63:3216-3225.
59. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-2299.
60. Hjeltnes G, Hollan I, Ferre O, et al. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol 2011; 40:422-427.
61. Ló pez-Longo FJ, Oliver-Miñ arro D, de la Torre I, et al. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61:419-424.
62. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364:2021-2029.
63. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-884.
64. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
65. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1089.
66. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165:978-984.
67. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366.
68. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578-1587.
69. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal anti-inflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59:1097-1104.
70. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006; 119:552-559.
71. Goodson NJ, Brookhart AM, Symmons DP, et al. Nonsteroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68:367-372.
72. Ravindran V, Rachapalli S, Choy EH. Safety of medium to long term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology 2009; 48:807-811.
73. Loddenkemper K, Bohl N, Perka C, et al. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. Rheumatol Int 2006; 26:331-336.
74. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 2008; 47:72-75.
75. Munro R,Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56:374-377.
76. Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008; 38:686-692.
77. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8:301-326.
78. Toms T, Panoulas V, Douglas K, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis Angiology 2011; 62:167-175.
79. Ruyssen-Witrand A, Fautrel B, Sarauxc A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78:23-30.
80. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:576-582.
81. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
82. VanHalm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8:R151.
83. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24:469-480.
84. Kremer JM. An analysis of risk factors and effect of treatment on the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:307.
85. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362-1370.
86. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rhematology 2010; 49:295-307.
87. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: a scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7:332-339.
88. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008; 117:244-279.
89. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
90. Al-Aly Z, Pan H, Zeringue A, et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011; 157:10-18.
91. Ljung L, Simard JF, Jacobsson L, et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012; 64:42-52.
92. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010; 69:1929-1933.
93. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti TNF therapy. Arthritis Care Res (Hoboken) 2012; 64:1282-1291.
94. Pollono EN, Lopez-Olivo MA, Lopez JA, et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29:947-955.
95. VanSijl AM, Peters MJ, Knol DL, et al. The effect on TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011; 41:393-400.
96. Daien CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012; 71:862-868.
97. Van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37:558-567.
98. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: pooled analysis of patients in clinical trials with up to 9.5 years of treatment. Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; 5-9 November 2011; Chicago, IL.
99. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 59:1821-1824.
100. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008; 59:1821-1824.
101. Roche Registration Limited. RoActemra 20 mg/ml concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City: Roche Registration Limited; 2011.
102. Gasparyan AY, Ayvazyan L, Cocco G, et al. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012; 18:1543-1555.
103. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011; 31:451-456.
104. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long term extensions. Mod Rheumatol 2010; 20:222-232.
105. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495-507.
106. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 2013; 52:45-52.
107. Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8:R186.
108. Crowson CS, Matteson EL, Roger VL, et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012; 110:420-424.